Conmed CORP 8-K filings

CONMED Corporation announced second quarter 2026 financial results, showing modest sales growth and a significant increase in adjusted diluted EPS, while updating full-year guidance.

CONMED Corporation announced the appointment of John E. Gallagher as its new Executive Vice President and Chief Financial Officer, effective July 15, 2026.

CONMED Corporation announced on June 3, 2026, that it has entered into agreements to repurchase approximately $645.2 million of its 2.25% Convertible Senior Notes due 2027.

CONMED Corporation announced the First Omnibus Amendment and Increased Facility Activation Notice, amending its credit agreement to secure an additional $450 million in delayed draw term loans.

CONMED Corporation announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors, effective July 1, 2026, expanding the board to nine members.

CONMED Corporation announced first quarter 2026 financial results, with sales down 1.3% year-over-year due to product line exits, but raised its full-year organic revenue growth outlook.

CONMED Corporation announced the appointment of Andrew Moller as Interim Principal Financial Officer, effective March 15, 2026.

CONMED Corporation announced its fourth quarter and full-year 2025 financial results, highlighting sales growth and providing its 2026 financial outlook.

CONMED Corporation presented preliminary 2026 financial guidance and highlighted key growth platforms at the J.P. Morgan Healthcare Conference.

CONMED Corporation announced the departure of its Chief Financial Officer, Todd Garner, who will transition to a Special Advisor role to ensure a smooth leadership change.

CONMED Corporation announced its strategic exit from gastroenterology product lines, including terminating its distribution agreement for the Gore VIABIL biliary stent, while reaffirming its 2025 financial guidance.

CONMED Corporation reported a 6.7% increase in third-quarter sales to $337.9 million, but GAAP diluted net earnings per share fell sharply to $0.09 from $1.57 year-over-year, while adjusted EPS rose slightly.

CONMED Corporation announced the appointment of Kim Kelderman, current President and CEO of Bio-Techne, to its Board of Directors, effective September 8, 2025.

CONMED Corporation's Board of Directors announced a quarterly cash dividend of $0.20 per share, payable on October 3, 2025.

CONMED Corporation announced second quarter 2025 financial results, reporting increased sales and adjusted diluted net earnings per share, alongside a decline in GAAP net earnings per share, and raised its full-year adjusted EPS guidance despite tariff impacts.

CONMED Corporation announced the amicable resignation of independent director Martha Aronson, effective July 7, 2025, as she transitions to become President and CEO of Merit Medical Systems, Inc.

CONMED Corporation has entered into an Eighth Amended and Restated Credit Agreement, securing new credit facilities totaling $750 million and extending the maturity of its term loan and revolving credit facilities to June 10, 2030.

CONMED Corporation held its 2025 annual meeting, approving the 2025 Long-Term Incentive Plan, electing directors, ratifying the appointment of PricewaterhouseCoopers LLP, and declaring a quarterly cash dividend of $0.20 per share.

CONMED Corporation reports a 2.9% increase in first-quarter sales and updates its full-year revenue and adjusted diluted net earnings per share guidance.

CONMED Corporation announces the appointment of Andrew Moller as Principal Accounting Officer, effective April 1, 2025, replacing Todd W. Garner, while Kimberly A. Lockwood is promoted to Senior Director of Financial Reporting.

CONMED Corporation expands its Board of Directors with the appointment of Mark Kaye and announces a quarterly cash dividend of $0.20 per share.

CONMED Corporation reports a solid finish to 2024 with increased sales and earnings, and anticipates further growth in 2025 despite currency headwinds.

CONMED Corporation presented at the J.P. Morgan Healthcare Conference, detailing its strategic focus on growth, profitability, and evolving its product mix towards higher-margin offerings.

CONMED Corporation's Board of Directors has declared a quarterly cash dividend of $0.20 per share.

CONMED Corporation announced a CEO transition and reported a 4.0% year-over-year increase in sales for the third quarter of 2024, alongside a revised full-year outlook.

CONMED Corporation released preliminary third-quarter 2024 financial information, projecting revenue between $315 million and $318 million and adjusted diluted net earnings per share growth exceeding prior guidance of 9% to 11%.

CONMED Corporation experienced temporary disruptions to its manufacturing and distribution facilities due to Hurricane Helene, but reports no significant damage and a return to normal operations.

CONMED Corporation's Vice President, Corporate Controller, Eric B. Staves, will depart on September 27, 2024, with Kimberly A. Lockwood named as Interim Corporate Controller effective September 30, 2024.

CONMED Corporation announced the termination of employment for Stanley W. (Bill) Peters, President of Advanced Surgical & Advanced Endoscopic Technologies, effective August 31, 2024.

CONMED Corporation's Board of Directors has declared a quarterly cash dividend of $0.20 per share.